Osaka University, Graduate School of Medicine
Osaka, 565-0871, Japan
NCT Number: NCT01815307
To compare efficacy and safety of Gemcitabine versus S-1 adjuvant therapy after hemihepatectomy.
Looking for future studies?
Notify Me20 year and older
All sexes
Interventional
Phase 2
Osaka, 565-0871, Japan
There is no standard adjuvant therapy after liver hemi-hepatectomy due to bile duct cancer, because of high surgical morbidity ratio and high adverse event ratio of adjuvant therapy. For example, our preliminary results showed that regular gemcitabine administration (1000mg/m2, day 1, 8, 15 every 4 weeks) after hemihepatectomy was too toxic and induced severe leukocytopenia and/or thrombocytopenia. Formerly, the investigators planned the study to decide more safety adjuvant protocol (recommend dose: RD) for Gemcitabine or S-1 after hemihepatectomy using Continuous Reassessment Method (CRM) analysis and decided the recommend doses. Note: In the former study, the investigators decided that tolerable ratio of Dose Limiting Toxicity (DLT) would be less than 10%.
Herein, the investigators planned the study to evaluate efficacy (recurrent free survival as primary outcome, and overall-survival as secondary outcome) and safety (as secondary outcome) in our recommended protocols, and to compare the efficacy as randomized control trial.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
1000mg/m2, day 1 every 2 weeks
Other names: gemzer
80mg/m2/day, day 1-28, every 6 weeks
Other names: TS-1
Time frame: One year
Duration: From randomization to evidenced recurrence or death. Rate: Number of patients with evidenced recurrence or death / number of total patients.
1 year recurrent free survival rate: recurrent free survival rate at one-year from the randomization
Time frame: Two years
Time frame: One year
Time frame: Two years
Time frame: 6 months
Time frame: 6 months
Time frame: 6 months
Time frame: an expected average of 2 years
Time frame: an expected average of 3 years
Kansai Hepatobiliary Oncology Group
Network
Randomized Phase II Study of Gemcitabine Versus S-1 Adjuvant Therapy After Hemihepatectomy for Biliary Tract Cancer
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT05512377
Biliary Tract Cancer, Biliary Tract Diseases
Mobile, Alabama, United States
View Trial DetailsNCT04776837
Biliary Tract Cancer, Biliary Tract Diseases
Boston, Massachusetts, United States
View Trial DetailsNCT07101874
Biliary Tract Cancer, Biliary Tract Diseases
Aichi, Japan
View Trial DetailsNCT06973161
Adnexal Diseases, Biliary Tract Cancer
Spartanburg, South Carolina, United States
View Trial Details